Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
CNY 40.9
(0.39%)
CNY 40.9
(0.39%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.36 Billion CNY | -4.6% |
| 2022 | 3.48 Billion CNY | 13.85% |
| 2021 | 3.05 Billion CNY | 11.68% |
| 2020 | 2.73 Billion CNY | -38.74% |
| 2019 | 4.47 Billion CNY | -3.9% |
| 2018 | 4.65 Billion CNY | 11.99% |
| 2017 | 4.15 Billion CNY | 8.35% |
| 2016 | 3.83 Billion CNY | 10.23% |
| 2015 | 3.47 Billion CNY | 20.64% |
| 2014 | 2.88 Billion CNY | 23.85% |
| 2013 | 2.32 Billion CNY | 27.26% |
| 2012 | 1.82 Billion CNY | 24.0% |
| 2011 | 1.47 Billion CNY | 13.65% |
| 2010 | 1.29 Billion CNY | 52.75% |
| 2009 | 849.59 Million CNY | 61.16% |
| 2008 | 527.16 Million CNY | 50.86% |
| 2007 | 349.43 Million CNY | 72.01% |
| 2006 | 203.14 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 958.43 Million CNY | 1.94% |
| 2024 Q2 | 940.23 Million CNY | -13.82% |
| 2024 Q1 | 1.09 Billion CNY | 21.18% |
| 2023 Q4 | 900.3 Million CNY | 16.62% |
| 2023 Q2 | 796.77 Million CNY | -10.22% |
| 2023 Q1 | 887.51 Million CNY | -4.94% |
| 2023 Q3 | 772.01 Million CNY | -3.11% |
| 2023 FY | 3.32 Billion CNY | -4.6% |
| 2022 Q1 | 935.24 Million CNY | 7.39% |
| 2022 Q4 | 933.68 Million CNY | 6.08% |
| 2022 Q3 | 880.18 Million CNY | 20.09% |
| 2022 FY | 3.48 Billion CNY | 13.85% |
| 2022 Q2 | 732.9 Million CNY | -21.63% |
| 2021 Q2 | 610.39 Million CNY | -20.31% |
| 2021 Q1 | 765.93 Million CNY | 26.74% |
| 2021 Q3 | 811.15 Million CNY | 32.89% |
| 2021 Q4 | 870.91 Million CNY | 7.37% |
| 2021 FY | 3.05 Billion CNY | 11.68% |
| 2020 Q3 | 598.42 Million CNY | -10.65% |
| 2020 Q4 | 604.34 Million CNY | 0.99% |
| 2020 FY | 2.73 Billion CNY | -38.74% |
| 2020 Q1 | 866.04 Million CNY | -4.44% |
| 2020 Q2 | 669.74 Million CNY | -22.67% |
| 2019 Q2 | 1.16 Billion CNY | -1.77% |
| 2019 FY | 4.47 Billion CNY | -3.9% |
| 2019 Q1 | 1.18 Billion CNY | 6.42% |
| 2019 Q3 | 1.2 Billion CNY | 3.48% |
| 2019 Q4 | 906.28 Million CNY | -24.99% |
| 2018 Q2 | 1.14 Billion CNY | 1.27% |
| 2018 Q4 | 1.11 Billion CNY | -11.93% |
| 2018 FY | 4.65 Billion CNY | 11.99% |
| 2018 Q1 | 1.12 Billion CNY | 7.1% |
| 2018 Q3 | 1.26 Billion CNY | 11.16% |
| 2017 Q3 | 1.06 Billion CNY | 0.46% |
| 2017 Q2 | 1.06 Billion CNY | 9.28% |
| 2017 FY | 4.15 Billion CNY | 8.35% |
| 2017 Q1 | 972.2 Million CNY | -3.19% |
| 2017 Q4 | 1.05 Billion CNY | -1.47% |
| 2016 Q2 | 976.62 Million CNY | 6.72% |
| 2016 FY | 3.83 Billion CNY | 10.23% |
| 2016 Q4 | 1 Billion CNY | 7.11% |
| 2016 Q1 | 915.15 Million CNY | 0.56% |
| 2016 Q3 | 937.51 Million CNY | -4.0% |
| 2015 Q2 | 874.95 Million CNY | 11.74% |
| 2015 FY | 3.47 Billion CNY | 20.64% |
| 2015 Q4 | 910.03 Million CNY | 0.04% |
| 2015 Q3 | 909.67 Million CNY | 3.97% |
| 2015 Q1 | 783.03 Million CNY | -12.96% |
| 2014 FY | 2.88 Billion CNY | 23.85% |
| 2014 Q4 | 899.59 Million CNY | 32.43% |
| 2014 Q1 | 650.91 Million CNY | -7.43% |
| 2014 Q3 | 679.28 Million CNY | 4.05% |
| 2014 Q2 | 652.84 Million CNY | 0.3% |
| 2013 Q2 | 533.66 Million CNY | 1.09% |
| 2013 FY | 2.32 Billion CNY | 27.26% |
| 2013 Q4 | 703.13 Million CNY | 24.94% |
| 2013 Q3 | 562.77 Million CNY | 5.46% |
| 2013 Q1 | 527.9 Million CNY | 9.22% |
| 2012 Q1 | 414.95 Million CNY | 4.33% |
| 2012 FY | 1.82 Billion CNY | 24.0% |
| 2012 Q2 | 434.13 Million CNY | 4.62% |
| 2012 Q3 | 496.45 Million CNY | 14.36% |
| 2012 Q4 | 483.33 Million CNY | -2.64% |
| 2011 Q2 | 355.89 Million CNY | -1.84% |
| 2011 Q1 | 362.54 Million CNY | 9.26% |
| 2011 FY | 1.47 Billion CNY | 13.65% |
| 2011 Q4 | 397.73 Million CNY | 10.88% |
| 2011 Q3 | 358.71 Million CNY | 0.79% |
| 2010 Q1 | 323.71 Million CNY | 6.23% |
| 2010 Q2 | 332.66 Million CNY | 2.77% |
| 2010 Q3 | 309.57 Million CNY | -6.94% |
| 2010 Q4 | 331.81 Million CNY | 7.18% |
| 2010 FY | 1.29 Billion CNY | 52.75% |
| 2009 Q1 | 161.09 Million CNY | 15.86% |
| 2009 Q2 | 192.36 Million CNY | 19.41% |
| 2009 Q3 | 191.4 Million CNY | -0.5% |
| 2009 FY | 849.59 Million CNY | 61.16% |
| 2009 Q4 | 304.72 Million CNY | 59.2% |
| 2008 Q3 | 120.87 Million CNY | 0.0% |
| 2008 FY | 527.16 Million CNY | 50.86% |
| 2008 Q4 | 139.03 Million CNY | 15.02% |
| 2007 FY | 349.43 Million CNY | 72.01% |
| 2006 FY | 203.14 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. | 7.89 Billion CNY | 57.349% |
| Blue Sail Medical Co.,Ltd. | 4.92 Billion CNY | 31.697% |
| Andon Health Co., Ltd. | 3.18 Billion CNY | -5.617% |
| Allmed Medical Products Co., Ltd | 2.75 Billion CNY | -22.08% |
| Improve Medical Instruments Co., Ltd. | 644.62 Million CNY | -422.065% |
| Tofflon Science and Technology Group Co., Ltd. | 5.64 Billion CNY | 40.349% |
| Truking Technology Limited | 6.8 Billion CNY | 50.54% |
| Jiangxi Sanxin Medtec Co.,Ltd. | 1.3 Billion CNY | -158.86% |
| Shenyang Xingqi Pharmaceutical Co.,Ltd | 1.46 Billion CNY | -129.314% |
| Autek China Inc. | 1.73 Billion CNY | -93.726% |
| Intco Medical Technology Co., Ltd. | 6.91 Billion CNY | 51.359% |
| Jiangsu Apon Medical Technology Co., Ltd. | 417.98 Million CNY | -705.142% |
| Winner Medical Co., Ltd. | 8.18 Billion CNY | 58.884% |
| Imeik Technology Development Co.,Ltd. | 2.85 Billion CNY | -17.918% |
| Zhonghong Pulin Medical Products Co., Ltd. | 2.1 Billion CNY | -59.855% |
| Caina Technology Co., Ltd. | 410.47 Million CNY | -719.874% |